Keli Jaqueline Staudt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Keli Jaqueline Staudt has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Christiane de Fátima Colet
Universidade Regional do Noroeste do Estado do Rio Grande do Sul
3 shared publications - Bibiana Verlindo de Araújo
Pharmaceutical Sciences Graduate Program Federal University of Rio Grande do Sul Porto Alegre Brazil
2 shared publications - Karine Raquel Uhdich Kleibert
Universidade Regional do Noroeste do Estado do Rio Grande do Sul, Brasil
2 shared publications Aline Schneider
Universidade Regional do Noroeste do Estado do Rio Grande do Sul
1 shared publication- Ana Paula Herrmann
Universidade Federal do Rio Grande do Sul
1 shared publication - Bruna Bernar Dias
Pharmacokinetics and PK/PD Modeling Laboratory, Pharmaceutical Sciences Graduate Program Federal University of Rio Grande Do Sul Porto Alegre Brazil
1 shared publication
Latest Publications
- Open Access
- 4 September 2026
- Published by Vigilancia Sanitaria em Debate: Sociedade, Ciencia y Tecnologia in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
- p. 1-8
Avaliação da atividade antimicrobiana in vitro do óleo essencial livre e nanoemulsão de Cymbopogon winterianus frente à Escherichia coli e Staphylococcus aureus
Introduction: Antimicrobial resistance represents a significant public health problem, driving the search for new therapeutic alternatives. Nanoencapsulation of Cymbopogon winterianus essential oil emerges as a promising strategy to enhance its stability and activity against clinically relevant microorganisms. Objective: To evaluate the antimicrobial activity of free Cymbopogon winterianus essential oil and nanoemulsion using the disk diffusion method and determine the minimum inhibitory concentration against Escherichia coli and Staphylococcus aureus. Method: To determine the lowest concentration capable of inhibiting microbial growth, microdilution was used, and the antibacterial susceptibility test was performed using the disk diffusion method, using multiple concentrations of the MIC. Results: The EO, both free and in citronella nanoemulsion, showed weak antibacterial activity against S. aureus, with an MIC of 2048 μg/mL for the free oil and 62,500 μg/mL for the nanoemulsion, and a moderate activity against E. coli, with an MIC of 512 μg/mL and 31,250 μg/mL for the nanoemulsion. In the susceptibility test, the oil did not show an inhibition halo at any concentration tested. Conclusions: It is concluded that citronella essential oil exhibited limited in vitro antibacterial activity against the evaluated strains, with better efficacy observed in the free form compared with nanoemulsion. The nanoemulsion did not demonstrate enhanced activity, suggesting that factors related to formulation and experimental conditions may have influenced its performance. These findings indicate that, under the tested conditions, incorporation into a nanoemulsion did not potentiate the antimicrobial effect of the essential oil.
- 4 September 2026
- Published by Vigilancia Sanitaria em Debate: Sociedade, Ciencia y Tecnologia in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
- p. 1-8
Open AccessAvaliação da atividade antimicrobiana in vitro do óleo essencial livre e nanoemulsão de Cymbopogon winterianus frente à Escherichia coli e Staphylococcus aureus
Introduction: Antimicrobial resistance represents a significant public health problem, driving the search for new therapeutic alternatives. Nanoencapsulation of Cymbopogon winterianus essential oil emerges as a promising strategy to enhance its stability and activity against clinically relevant microorganisms. Objective: To evaluate the antimicrobial activity of free Cymbopogon winterianus essential oil and nanoemulsion using the disk diffusion method and determine the minimum inhibitory concentration against Escherichia coli and Staphylococcus aureus. Method: To determine the lowest concentration capable of inhibiting microbial growth, microdilution was used, and the antibacterial susceptibility test was performed using the disk diffusion method, using multiple concentrations of the MIC. Results: The EO, both free and in citronella nanoemulsion, showed weak antibacterial activity against S. aureus, with an MIC of 2048 μg/mL for the free oil and 62,500 μg/mL for the nanoemulsion, and a moderate activity against E. coli, with an MIC of 512 μg/mL and 31,250 μg/mL for the nanoemulsion. In the susceptibility test, the oil did not show an inhibition halo at any concentration tested. Conclusions: It is concluded that citronella essential oil exhibited limited in vitro antibacterial activity against the evaluated strains, with better efficacy observed in the free form compared with nanoemulsion. The nanoemulsion did not demonstrate enhanced activity, suggesting that factors related to formulation and experimental conditions may have influenced its performance. These findings indicate that, under the tested conditions, incorporation into a nanoemulsion did not potentiate the antimicrobial effect of the essential oil.
- Open Access
- 21 May 2026
- Published by Vigilancia Sanitaria em Debate: Sociedade, Ciencia y Tecnologia in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
- p. 1-10
Evaluation of sleep quality during pharmacotherapeutic: follow-up
Introduction: Pharmacotherapeutic monitoring (PM) in mental health can lead to significant benefits for patients; however, the involvement of clinical pharmacists in this context is underdiscussed in literature. Often, the addition of new medications is carried out to address complaints brought by patients, as is the case with insomnia complaints, where benzodiazepines are commonly added to pharmacotherapy. Objective: The aim of this study was to assess the sleep quality of psychiatric patients enrolled in a pharmacotherapeutic monitoring service within a public mental health outpatient clinic. Method: A total of 16 patients were included in the analysis. Patient data obtained from the Medical Records of the Pharmaceutical Clinical Service under the Ministry of Health were utilized. The assessment tools employed included PSQI-Br, PHQ-9, and GAD-7, with further analysis conducted using the multiple linear regression test to explore the relationship between various variables and the PSQI-Br score. Results: The findings revealed that 68.75% of the patients exhibited sleep disturbances, 61.53% displayed moderate to severe depressive symptoms, and 35.7% showed severe anxiety levels. Significant correlation was observed between PSQI scores and the total hours of sleep (p = 0.003). A total of 83 pharmaceutical interventions were implemented as part of the treatment regimen. Conclusios: The study concludes that a considerable proportion of mental health patients experience poor sleep quality or an underlying sleep disorder, posing challenges in the management of their condition. Therefore, it is imperative to prioritize the evaluation of sleep quality to mitigate psychological deterioration and enhance the effectiveness of drug therapy by incorporating strategies focusing on sleep hygiene within the framework of the Unified Health System.
- 21 May 2026
- Published by Vigilancia Sanitaria em Debate: Sociedade, Ciencia y Tecnologia in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
- p. 1-10
Open AccessEvaluation of sleep quality during pharmacotherapeutic: follow-up
Introduction: Pharmacotherapeutic monitoring (PM) in mental health can lead to significant benefits for patients; however, the involvement of clinical pharmacists in this context is underdiscussed in literature. Often, the addition of new medications is carried out to address complaints brought by patients, as is the case with insomnia complaints, where benzodiazepines are commonly added to pharmacotherapy. Objective: The aim of this study was to assess the sleep quality of psychiatric patients enrolled in a pharmacotherapeutic monitoring service within a public mental health outpatient clinic. Method: A total of 16 patients were included in the analysis. Patient data obtained from the Medical Records of the Pharmaceutical Clinical Service under the Ministry of Health were utilized. The assessment tools employed included PSQI-Br, PHQ-9, and GAD-7, with further analysis conducted using the multiple linear regression test to explore the relationship between various variables and the PSQI-Br score. Results: The findings revealed that 68.75% of the patients exhibited sleep disturbances, 61.53% displayed moderate to severe depressive symptoms, and 35.7% showed severe anxiety levels. Significant correlation was observed between PSQI scores and the total hours of sleep (p = 0.003). A total of 83 pharmaceutical interventions were implemented as part of the treatment regimen. Conclusios: The study concludes that a considerable proportion of mental health patients experience poor sleep quality or an underlying sleep disorder, posing challenges in the management of their condition. Therefore, it is imperative to prioritize the evaluation of sleep quality to mitigate psychological deterioration and enhance the effectiveness of drug therapy by incorporating strategies focusing on sleep hygiene within the framework of the Unified Health System.
- Open Access
- 28 January 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (4) , 638-648
Pharmacokinetic/pharmacodynamic modeling of cortical dopamine concentrations after quetiapine lipid core nanocapsules administration to schizophrenia phenotyped rats
Schizophrenia (SCZ) response to pharmacological treatment is highly variable. Quetiapine (QTP) administered as QTP lipid core nanocapsules (QLNC) has been shown to modulate drug delivery to the brain of SCZ phenotyped rats (SPR). In the present study, we describe the brain concentration-effect relationship after administrations of QTP as a solution or QLNC to SPR and naive animals. A semimechanistic pharmacokinetic (PK) model describing free QTP concentrations in the brain was linked to a pharmacodynamic (PD) model to correlate the drug kinetics to changes in dopamine (DA) medial prefrontal cortex extracellular concentrations determined by intracerebral microdialysis. Different structural models were investigated to fit DA concentrations after QTP dosing, and the final model describes the synthesis, release, and elimination of DA using a pool compartment. The results show that nanoparticles increase QTP brain concentrations and DA peak after drug dosing to SPR. To the best of our knowledge, this is the first study that combines microdialysis and PK/PD modeling in a neurodevelopmental model of SCZ to investigate how a nanocarrier can modulate drug PK and PD, contributing to the development of new treatment strategies for SCZ.
- 28 January 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (4) , 638-648
Open AccessPharmacokinetic/pharmacodynamic modeling of cortical dopamine concentrations after quetiapine lipid core nanocapsules administration to schizophrenia phenotyped rats
Schizophrenia (SCZ) response to pharmacological treatment is highly variable. Quetiapine (QTP) administered as QTP lipid core nanocapsules (QLNC) has been shown to modulate drug delivery to the brain of SCZ phenotyped rats (SPR). In the present study, we describe the brain concentration-effect relationship after administrations of QTP as a solution or QLNC to SPR and naive animals. A semimechanistic pharmacokinetic (PK) model describing free QTP concentrations in the brain was linked to a pharmacodynamic (PD) model to correlate the drug kinetics to changes in dopamine (DA) medial prefrontal cortex extracellular concentrations determined by intracerebral microdialysis. Different structural models were investigated to fit DA concentrations after QTP dosing, and the final model describes the synthesis, release, and elimination of DA using a pool compartment. The results show that nanoparticles increase QTP brain concentrations and DA peak after drug dosing to SPR. To the best of our knowledge, this is the first study that combines microdialysis and PK/PD modeling in a neurodevelopmental model of SCZ to investigate how a nanocarrier can modulate drug PK and PD, contributing to the development of new treatment strategies for SCZ.
- Open Access
- 14 December 2023
- Published by Universidade Estadual de Maringa in Acta Scientiarum. Health Sciences
- Vol. 46 (1) , e65536
Assessment of oxidative stress biomarkers in patients before pharmacological treatment for rheumatoid arthritis
Rheumatoid Arthritis (RA) significantly decreases the functional capacity of 1% of the world's population, and it is believed that oxidative stress may be one of its triggering factors. Thus, the present study evaluated the biomarkers of oxidative stress in patients with rheumatoid arthritis before pharmacological treatment and their relationship with the DAS 28 score. This is an observational, cross-sectional study with a quantitative and analytical approach. Patients treated at a rheumatology clinic in the city of Ijuí/RS, with a diagnosis of rheumatoid arthritis, were selected and compared with the control group. Data collection took place between August and September 2020. In the 18 patients who participated in the research, higher values of SOD (p = 0.045), NP-SH (p ≤ 0.000) and TBARS (p = 0.005), and reduced levels of CAT (p ≤ 0.000) were found, when compared to the control. The enzymatic levels of the patients showed a significant association with body mass index. Furthermore, in this study, the pain complaint did not correlate with oxidative stress markers. This study showed changes in oxidative stress biomarkers in patients with RA before pharmacological treatment, demonstrating that these are indicative of a worse prognosis, which is estimated to be minimized with adequate pharmacological treatment.
- 14 December 2023
- Published by Universidade Estadual de Maringa in Acta Scientiarum. Health Sciences
- Vol. 46 (1) , e65536
Open AccessAssessment of oxidative stress biomarkers in patients before pharmacological treatment for rheumatoid arthritis
Rheumatoid Arthritis (RA) significantly decreases the functional capacity of 1% of the world's population, and it is believed that oxidative stress may be one of its triggering factors. Thus, the present study evaluated the biomarkers of oxidative stress in patients with rheumatoid arthritis before pharmacological treatment and their relationship with the DAS 28 score. This is an observational, cross-sectional study with a quantitative and analytical approach. Patients treated at a rheumatology clinic in the city of Ijuí/RS, with a diagnosis of rheumatoid arthritis, were selected and compared with the control group. Data collection took place between August and September 2020. In the 18 patients who participated in the research, higher values of SOD (p = 0.045), NP-SH (p ≤ 0.000) and TBARS (p = 0.005), and reduced levels of CAT (p ≤ 0.000) were found, when compared to the control. The enzymatic levels of the patients showed a significant association with body mass index. Furthermore, in this study, the pain complaint did not correlate with oxidative stress markers. This study showed changes in oxidative stress biomarkers in patients with RA before pharmacological treatment, demonstrating that these are indicative of a worse prognosis, which is estimated to be minimized with adequate pharmacological treatment.
- Open Access
- 13 September 2023
- Published by Universidade Federal da Bahia in Revista de Ciências Médicas e Biológicas
- Vol. 22 (2) , 251-259
Variáveis antropométricas, clínicas e medicamentosas de usuários de varfarina após acompanhamento farmacoterapêutico
Introdução: a varfarina é um medicamento anticoagulante para o tratamento de doenças cardíacas, tromboembólicas e de hipercoagulabilidade. É considerado potencialmente perigoso devido à janela terapêutica estreita e grande variabilidade de resposta. Objetivo: avaliar o impacto do acompanhamento farmacoterapêutico sobre o uso de medicamentos e interações medicamentosas de pacientes do sistema público de saúde que fazem uso de varfarina, bem como associar o acompanhamento às medidas clínicas de pressão arterial e o índice de massa corporal. Metodologia: 47 pacientes participaram da pesquisa, onde foi realizado um ensaio clínico randomizado de dois braços, paralelo e controlado, que compara o grupo intervenção (n=23), através do acompanhamento farmacoterapêutico em pacientes do sistema público de saúde do município de Ijuí que fazem uso de varfarina, com um grupo controle (n=24), sem acompanhamento farmacoterapêutico. Resultados: neste estudo não foi demonstrada associação do acompanhamento farmacoterapêutico e medidas antropométricas como IMC e circunferência abdominal, mas verifica-se a alta prevalência dessas variáveis alteradas, como sobrepeso e obesidade. Houve melhora da pressão arterial no grupo intervenção em comparação ao grupo controle, o que demonstra o benefício do acompanhamento. Discussão: o controle da anticoagulação pode ser prejudicado por alimentação, uso de medicamentos, idade e doenças associadas, e seu uso requer o monitoramento dos níveis de INR e avaliação da adesão ao tratamento. Conclusão: os usuários de varfarina estão suscetíveis a sangramentos, tromboses, interações medicamentosas, além dos próprios fatores de risco decorrentes da obesidade, hipertensão e adiposidade abdominal, sendo fundamental o acompanhamento destes pacientes para se evitar possíveis efeitos negativos da medicação.
- 13 September 2023
- Published by Universidade Federal da Bahia in Revista de Ciências Médicas e Biológicas
- Vol. 22 (2) , 251-259
Open AccessVariáveis antropométricas, clínicas e medicamentosas de usuários de varfarina após acompanhamento farmacoterapêutico
Introdução: a varfarina é um medicamento anticoagulante para o tratamento de doenças cardíacas, tromboembólicas e de hipercoagulabilidade. É considerado potencialmente perigoso devido à janela terapêutica estreita e grande variabilidade de resposta. Objetivo: avaliar o impacto do acompanhamento farmacoterapêutico sobre o uso de medicamentos e interações medicamentosas de pacientes do sistema público de saúde que fazem uso de varfarina, bem como associar o acompanhamento às medidas clínicas de pressão arterial e o índice de massa corporal. Metodologia: 47 pacientes participaram da pesquisa, onde foi realizado um ensaio clínico randomizado de dois braços, paralelo e controlado, que compara o grupo intervenção (n=23), através do acompanhamento farmacoterapêutico em pacientes do sistema público de saúde do município de Ijuí que fazem uso de varfarina, com um grupo controle (n=24), sem acompanhamento farmacoterapêutico. Resultados: neste estudo não foi demonstrada associação do acompanhamento farmacoterapêutico e medidas antropométricas como IMC e circunferência abdominal, mas verifica-se a alta prevalência dessas variáveis alteradas, como sobrepeso e obesidade. Houve melhora da pressão arterial no grupo intervenção em comparação ao grupo controle, o que demonstra o benefício do acompanhamento. Discussão: o controle da anticoagulação pode ser prejudicado por alimentação, uso de medicamentos, idade e doenças associadas, e seu uso requer o monitoramento dos níveis de INR e avaliação da adesão ao tratamento. Conclusão: os usuários de varfarina estão suscetíveis a sangramentos, tromboses, interações medicamentosas, além dos próprios fatores de risco decorrentes da obesidade, hipertensão e adiposidade abdominal, sendo fundamental o acompanhamento destes pacientes para se evitar possíveis efeitos negativos da medicação.
- 13 June 2022
- Published by Taylor & Francis in Future Microbiology
- Vol. 17 (12) , 969-982
Experimental Models for Pharmacokinetic and Pharmacodynamic Studies of Antifungals Used in Cryptococcosis Treatment
Studies on cryptococcosis in the mammal animal model have demonstrated the occurrence of central nervous system infection and similarities in fungal pathogenicity with clinical and immunological fe...
- 13 June 2022
- Published by Taylor & Francis in Future Microbiology
- Vol. 17 (12) , 969-982
Experimental Models for Pharmacokinetic and Pharmacodynamic Studies of Antifungals Used in Cryptococcosis Treatment
Studies on cryptococcosis in the mammal animal model have demonstrated the occurrence of central nervous system infection and similarities in fungal pathogenicity with clinical and immunological fe...